• Je něco špatně v tomto záznamu ?

Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry

M. Vrablik, K. Raslová, B. Vohnout, V. Blaha, M. Satny, O. Kyselak, M. Vaclova, R. Urbanek, J. Maskova, V. Soska, T. Freiberger,

. 2018 ; 277 (-) : 355-361. [pub] -

Jazyk angličtina Země Irsko

Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19045218

BACKGROUND AND AIMS: Despite the high prevalence of familial hypercholesterolemia (FH) and available effective lipid-lowering therapy, most of the individuals with this disorder remain undiagnosed and undertreated. The aim of the PLANET registry was to assess the real-life attainment of low-density lipoprotein cholesterol (LDL-C) therapeutic target level in patients with heterozygous FH, to characterize prescribed lipid-lowering therapy with assessment of its efficiency according to the attainment of the target LDL-C level, and to characterize cardiovascular events observed in this patient population again in relation to LDL-C target level attainment. METHODS: PLANET registry was designed as a non-interventional, retrospective, cross-sectional, multicentre disease registry for adult patients with heterozygous FH in the Czech Republic and Slovakia. RESULTS: Overall, 1755 patients were enrolled at 32 sites specialized in FH treatment. 15.4% of patients attained the target LDL-C value. The proportion of patients with LDL-C goal achievement increased to 17.3% in the subgroup of patients receiving high-intensity statin therapy (54.6% of study population). Out of 55 patients receiving inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9), 61.8% reached the LDL-C treatment goal. Of all cardiovascular events reported, 14.0% occurred in patients attaining the LDL-C goal, while it was 86.0% in the not-at-target group. It was documented (p=0.004) that the longer is the patient in care at the specialized FH centre, the higher is the probability that he/she will attain the target LDL-C level. CONCLUSIONS: Although target LDL-C level attainment remains relatively low, the likelihood of LDL-C goal attainment increases with duration of specialized care.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045218
003      
CZ-PrNML
005      
20220322154154.0
007      
ta
008      
200109s2018 ie f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.atherosclerosis.2018.08.008 $2 doi
035    __
$a (PubMed)30270071
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Vrablik, Michal $u Third Department of Internal Medicine, General University Hospital and First Faculty of Medicine, Charles University, U Nemocnice 1, 128 08 Prague 2, Czech Republic.
245    10
$a Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry / $c M. Vrablik, K. Raslová, B. Vohnout, V. Blaha, M. Satny, O. Kyselak, M. Vaclova, R. Urbanek, J. Maskova, V. Soska, T. Freiberger,
520    9_
$a BACKGROUND AND AIMS: Despite the high prevalence of familial hypercholesterolemia (FH) and available effective lipid-lowering therapy, most of the individuals with this disorder remain undiagnosed and undertreated. The aim of the PLANET registry was to assess the real-life attainment of low-density lipoprotein cholesterol (LDL-C) therapeutic target level in patients with heterozygous FH, to characterize prescribed lipid-lowering therapy with assessment of its efficiency according to the attainment of the target LDL-C level, and to characterize cardiovascular events observed in this patient population again in relation to LDL-C target level attainment. METHODS: PLANET registry was designed as a non-interventional, retrospective, cross-sectional, multicentre disease registry for adult patients with heterozygous FH in the Czech Republic and Slovakia. RESULTS: Overall, 1755 patients were enrolled at 32 sites specialized in FH treatment. 15.4% of patients attained the target LDL-C value. The proportion of patients with LDL-C goal achievement increased to 17.3% in the subgroup of patients receiving high-intensity statin therapy (54.6% of study population). Out of 55 patients receiving inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9), 61.8% reached the LDL-C treatment goal. Of all cardiovascular events reported, 14.0% occurred in patients attaining the LDL-C goal, while it was 86.0% in the not-at-target group. It was documented (p=0.004) that the longer is the patient in care at the specialized FH centre, the higher is the probability that he/she will attain the target LDL-C level. CONCLUSIONS: Although target LDL-C level attainment remains relatively low, the likelihood of LDL-C goal attainment increases with duration of specialized care.
650    _2
$a anticholesteremika $x škodlivé účinky $x terapeutické užití $7 D000924
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a kardiovaskulární nemoci $x epidemiologie $x prevence a kontrola $7 D002318
650    _2
$a LDL-cholesterol $x krev $7 D008078
650    _2
$a průřezové studie $7 D003430
650    _2
$a down regulace $7 D015536
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a ezetimib $x terapeutické užití $7 D000069438
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genetické markery $7 D005819
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a heterozygot $7 D006579
650    _2
$a lidé $7 D006801
650    _2
$a statiny $x terapeutické užití $7 D019161
650    _2
$a hyperlipoproteinemie typ II $x krev $x farmakoterapie $x epidemiologie $x genetika $7 D006938
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $7 D009154
650    _2
$a fenotyp $7 D010641
650    _2
$a proproteinkonvertasa subtilisin/kexin typu 9 $x metabolismus $7 D000071449
650    _2
$a registrace $7 D012042
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a inhibitory serinových proteinas $x terapeutické užití $7 D015842
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
650    _2
$a PCSK9 inhibitory $7 D000091362
651    _2
$a Česká republika $x epidemiologie $7 D018153
651    _2
$a Slovenská republika $x epidemiologie $7 D018154
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Raslová, Katarina $u Coordination Centre for Familial Hypercholesterolemia and Institute of Nutrition, Slovak Medical University, Limbova 14, 833 03 Bratislava, Slovak Republic.
700    1_
$a Vohnout, Branislav $u Coordination Centre for Familial Hypercholesterolemia and Institute of Nutrition, Slovak Medical University, Limbova 14, 833 03 Bratislava, Slovak Republic.
700    1_
$a Blaha, Vladimir $u Internal Gerontometabolic Department, University Hospital Hradec Kralove, Sokolska 408, 500 05 Hradec Kralove, Czech Republic.
700    1_
$a Satny, Martin $u Third Department of Internal Medicine, General University Hospital and First Faculty of Medicine, Charles University, U Nemocnice 1, 128 08 Prague 2, Czech Republic.
700    1_
$a Kyselak, Ondrej $u Department of Clinical Biochemistry and the International Clinical Research Center - Department of Cardiovascular Diseases, St. Anne's University Hospital Brno, Pekarska 53, 656 91 Brno, Czech Republic.
700    1_
$a Vaclová, Martina $u Third Department of Internal Medicine, General University Hospital and First Faculty of Medicine, Charles University, U Nemocnice 1, 128 08 Prague 2, Czech Republic. $7 xx0160828
700    1_
$a Urbanek, Robin $u Obezita-Ormiga, Koterova 5546, 760 01 Zlin, Czech Republic.
700    1_
$a Maskova, Jana $u NEOX Clinical Research, V Jame 1, 110 00 Prague 1, Czech Republic.
700    1_
$a Soska, Vladimir $u Department of Clinical Biochemistry and the International Clinical Research Center - Department of Cardiovascular Diseases, St. Anne's University Hospital Brno, Pekarska 53, 656 91 Brno, Czech Republic; Second Department of Internal Medicine, Faculty of Medicine Masaryk University and St. Anne's University Hospital Brno, Pekarska 53, 656 91 Brno, Czech Republic.
700    1_
$a Freiberger, Tomas $u Centre for Cardiovascular Surgery and Transplantation, Pekarska 53, 656 91 Brno, Czech Republic; Ceitec and Medical Faculty of Masaryk University, Zerotinovo nam. 617/9, 601 77 Brno, Czech Republic. Electronic address: tomas.freiberger@cktch.cz.
773    0_
$w MED00009284 $t Atherosclerosis $x 1879-1484 $g Roč. 277, č. - (2018), s. 355-361
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30270071 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20220322154151 $b ABA008
999    __
$a ok $b bmc $g 1483487 $s 1083891
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 277 $c - $d 355-361 $e - $i 1879-1484 $m Atherosclerosis $n Atherosclerosis $x MED00009284
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace